Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
HCC
PD-L1
biomarkers
hepatocellular carcinoma
immunotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
10
2021
accepted:
01
12
2021
entrez:
3
1
2022
pubmed:
4
1
2022
medline:
4
1
2022
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy worldwide, still representing an important cause of cancer-related death. Over the next few years, novel systemic treatment options have emerged. Among these, immune checkpoint inhibitors (ICIs) have been widely evaluated and are under assessment, as monotherapy or in combination with other anticancer agents in treatment-naïve and previously treated patients. In particular, the approval of the PD-L1 inhibitor atezolizumab plus the antiangiogenic agent bevacizumab as front-line treatment for advanced HCC has led to the adoption of this combination in this setting, and the IMbrave 150 phase III trial has established a novel standard of care. However, several questions remain unanswered, including the identification of reliable predictors of response to ICIs in HCC patients. In the current paper, we will provide an updated overview of potentially useful predictive biomarkers of response to immunotherapy in advanced HCC. A literature search was conducted in September 2021 of Pubmed/Medline, Cochrane library and Scopus databases.
Identifiants
pubmed: 34976841
doi: 10.3389/fonc.2021.803133
pmc: PMC8718608
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
803133Informations de copyright
Copyright © 2021 Rizzo, Ricci, Di Federico, Frega, Palloni, Tavolari and Brandi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Pharmacol Ther. 2018 Sep;189:45-62
pubmed: 29669262
Mol Cell. 2015 Nov 19;60(4):547-60
pubmed: 26590714
Adv Ther. 2019 Oct;36(10):2638-2678
pubmed: 31410780
Clin Cancer Res. 2019 Dec 15;25(24):7413-7423
pubmed: 31515453
Nat Rev Clin Oncol. 2018 Jun;15(6):353-365
pubmed: 29599476
Cancers (Basel). 2019 Oct 14;11(10):
pubmed: 31615069
Expert Opin Investig Drugs. 2019 Aug;28(8):695-708
pubmed: 31359805
J Immunol Res. 2021 Feb 22;2021:6661406
pubmed: 33681388
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616
pubmed: 30061739
Expert Opin Investig Drugs. 2017 Dec;26(12):1341-1355
pubmed: 28984489
Gut. 2019 Mar;68(3):385-388
pubmed: 30530851
J Immunother Cancer. 2019 Jul 23;7(1):193
pubmed: 31337439
Hepatology. 2016 Dec;64(6):2038-2046
pubmed: 27359084
Cancer Immunol Immunother. 2021 Feb;70(2):377-389
pubmed: 32761426
Biomed Res Int. 2021 Jan 5;2021:9798231
pubmed: 33506049
Expert Opin Investig Drugs. 2021 Aug 30;:1-9
pubmed: 34429006
Cancers (Basel). 2021 May 30;13(11):
pubmed: 34070929
Immunotherapy. 2021 Jun;13(8):637-644
pubmed: 33820447
Crit Rev Immunol. 2019;39(5):313-328
pubmed: 32422014
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Front Oncol. 2018 Jul 13;8:269
pubmed: 30057891
Cancer Med. 2019 Dec;8(17):7161-7173
pubmed: 31568700
Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):329-339
pubmed: 28871000
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Oncotarget. 2019 Jun 18;10(40):4018-4025
pubmed: 31258846
J Hepatol. 2020 Feb;72(2):307-319
pubmed: 31954494
Nat Rev Cancer. 2016 Jan;16(1):35-42
pubmed: 26667849
Expert Opin Investig Drugs. 2021 Dec 1;:1-9
pubmed: 34798793
Cancer Discov. 2019 Aug;9(8):1124-1141
pubmed: 31186238
Ann Oncol. 2020 Jun;31(6):798-806
pubmed: 32209338
Virchows Arch. 2016 May;468(5):511-25
pubmed: 26915032
J Cell Physiol. 2020 Dec;235(12):9304-9316
pubmed: 32330311
Genome Med. 2021 Jun 23;13(1):107
pubmed: 34162429
EBioMedicine. 2019 Apr;42:363-374
pubmed: 30885723
Int Immunopharmacol. 2021 Mar;92:107333
pubmed: 33486322
JAMA Oncol. 2021 Jan 1;7(1):113-123
pubmed: 33090190
J Pathol Clin Res. 2020 Apr;6(2):138-145
pubmed: 31849189
Semin Liver Dis. 2021 May;41(2):136-141
pubmed: 33957697
Cancer Immunol Res. 2021 Apr;9(4):365-370
pubmed: 34003768
Cancer Immunol Immunother. 2021 Mar;70(3):667-677
pubmed: 32876735
Future Oncol. 2021 Mar;17(7):755-757
pubmed: 33508960
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Mol Cell. 2020 Oct 1;80(1):21-28
pubmed: 32810436
Curr Protoc Mol Biol. 2018 Apr;122(1):e59
pubmed: 29851291
Expert Opin Investig Drugs. 2015;24(8):1075-82
pubmed: 26108356
Expert Rev Anticancer Ther. 2018 Dec;18(12):1169-1175
pubmed: 30304963
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32217756
Bull Cancer. 2019 Feb;106(2):119-128
pubmed: 30713006
Clin Cancer Res. 2019 Apr 1;25(7):2116-2126
pubmed: 30373752
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):e15-e21
pubmed: 28877075
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
Mamm Genome. 2021 Aug;32(4):223-231
pubmed: 33783613
Nature. 2021 Apr;592(7854):450-456
pubmed: 33762733
Expert Opin Investig Drugs. 2019 Jan;28(1):1-5
pubmed: 30474425
Cancer Treat Res Commun. 2021;27:100328
pubmed: 33549983
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
J Clin Oncol. 2021 Sep 20;39(27):2991-3001
pubmed: 34292792
Nature. 2009 Apr 9;458(7239):719-24
pubmed: 19360079
Vaccines (Basel). 2020 Aug 08;8(3):
pubmed: 32784389
Hepatobiliary Surg Nutr. 2021 Apr;10(2):180-192
pubmed: 33898559
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Immunotherapy. 2018 Feb;10(2):93-105
pubmed: 29145737
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Cancer Treat Res Commun. 2021;27:100353
pubmed: 33770662
N Engl J Med. 2020 May 14;382(20):1953-1955
pubmed: 32402168
Cancer Treat Res Commun. 2020;25:100239
pubmed: 33271494
Hepatol Res. 2009 Mar;39(3):266-73
pubmed: 19054153
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Cancers (Basel). 2020 Apr 27;12(5):
pubmed: 32349374
J Immunother Cancer. 2019 Apr 17;7(1):108
pubmed: 30995949
Expert Opin Investig Drugs. 2020 Sep;29(9):1005-1023
pubmed: 32643447
Liver Int. 2021 Jan;41(1):192-203
pubmed: 33098208
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Annu Rev Genomics Hum Genet. 2016 Aug 31;17:95-115
pubmed: 27362342
Expert Opin Investig Drugs. 2019 Nov;28(11):941-949
pubmed: 31590579
Cancer Control. 2020 Jan-Dec;27(1):1073274820977114
pubmed: 33269615
Open Biol. 2018 Jun;8(6):
pubmed: 29875199
J Exp Clin Cancer Res. 2019 Jun 13;38(1):255
pubmed: 31196207
Nat Rev Clin Oncol. 2019 Feb;16(2):81-104
pubmed: 30356138
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Nat Rev Gastroenterol Hepatol. 2021 Aug;18(8):525-543
pubmed: 33850328
Int Immunopharmacol. 2020 Mar;80:106247
pubmed: 32007710
Oncogene. 2020 Apr;39(18):3620-3637
pubmed: 32157213
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
J Hepatol. 2020 Feb;72(2):342-352
pubmed: 31954496
Nat Med. 2016 Nov;22(11):1342-1350
pubmed: 27694933
JAMA Oncol. 2016 Jan;2(1):46-54
pubmed: 26562159
Expert Opin Investig Drugs. 2017 Dec;26(12):1317-1319
pubmed: 29046065
Oncogene. 2021 Jan;40(1):140-151
pubmed: 33097857
Expert Opin Investig Drugs. 2021 Jun 30;:1-8
pubmed: 34167433
Transl Gastroenterol Hepatol. 2020 Jan 05;5:8
pubmed: 32190776